Valneva Reports Further Positive Pivotal Phase 3 Data in Adolescents for its Single-Shot Chikungunya Vaccine
GlobeNewswire
*Results Intended to Support Filing for Potential Label Extension for Use in Adolescents**Saint-Herblain (France), May 13, 2024*..